3 Reasons Pfizer's Imminent Upjohn-Mylan Merger Is Great News for Investors

By Motley Fool

Pfizer's revenue growth will improve once the Upjohn-Mylan merger wraps up. The big drugmaker will receive a nice $12 billion cash windfall from the deal. Pfizer shareholders will still receive a combined dividend (including a dividend from the new entity formed by the merger) that's close to what they receive now.

…read more

Via:: Sports Headlines

      

Get 20% off hat purchases for ONLY $5! Join our LIDS Club @ lids.com.
%d bloggers like this: